GO:0050859 negative regulation of B cell receptor signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0050859 describes any process that stops, prevents, or reduces the frequency, rate or extent of signaling pathways initiated by cross-linking of an antigen receptor on a B cell.
• B cell receptor (BCR) signaling is initiated by antigen-induced receptor clustering and is propagated by tyrosine kinases such as SYK and BTK, and by adaptor proteins including CD19 and BLNK.
• Negative regulation of BCR signaling is essential for preventing autoimmunity and lymphomagenesis; its failure contributes to diseases such as Burkitt lymphoma and primary atopic disorders.
• Key negative regulators include phosphatases (SHIP1, SHP1, PTEN), E3 ubiquitin ligases (CBL, CBLB, ITCH), and cytoskeletal regulators such as non-muscle myosin II.
• Transcription factors and signaling thresholds, such as Ikaros and p66Shc, set the sensitivity of B cells to negative selection and chemokine receptor signaling.
• Experimental dissection of GO:0050859 relies on CRISPR knockout, point-mutation, knock-in, and overexpression models combined with phospho-proteomics, imaging, and functional assays.
Description
The B cell receptor (BCR) signaling pathway is a central checkpoint in humoral immunity, controlling B cell activation, proliferation, differentiation, and survival. Antigen-induced cross-linking of the BCR triggers a cascade of tyrosine phosphorylation events that must be tightly regulated to avoid excessive or self-reactive responses. The Gene Ontology term GO:0050859, negative regulation of B cell receptor signaling pathway, captures the diverse cellular processes that attenuate this cascade. Understanding these negative regulatory mechanisms is critical because their dysregulation is linked to autoimmune diseases, immunodeficiencies, and B cell malignancies. This article synthesizes authoritative QuickGO annotation data and published literature to provide a research-grade overview of GO:0050859, its molecular players, disease relevance, and experimental strategies for investigation.
negative regulation of B cell receptor signaling pathway At A Glance
| GO ID | GO:0050859 |
|---|---|
| GO term | negative regulation of B cell receptor signaling pathway |
| Ontology | biological_process |
| Synonym | down regulation of B cell receptor signaling pathway; inhibition of B cell receptor signaling pathway; negative regulation of B-cell receptor signalling pathway |
| Major function | Attenuation or termination of BCR-initiated signal transduction to maintain immune homeostasis |
| Related processes | B cell activation, B cell anergy, negative selection, autoimmunity prevention |
| Key regulators | SHIP1, SHP1, PTEN, CBL, CBLB, ITCH, p66Shc, Ikaros, non-muscle myosin II |
| Disease relevance | Burkitt lymphoma, primary atopic disorders, autoimmune diseases, B cell immunodeficiencies |
What Is GO:0050859?
GO:0050859 is defined as any process that stops, prevents, or reduces the frequency, rate or extent of signaling pathways initiated by the cross-linking of an antigen receptor on a B cell. In other words, it encompasses all molecular events that dampen or terminate BCR-initiated signal transduction, including the action of inhibitory phosphatases, ubiquitin ligases, adaptor proteins, and cytoskeletal remodeling factors.
Why Is negative regulation of B cell receptor signaling pathway Important in Cell Biology?
Negative regulation of BCR signaling is essential for immune tolerance and for preventing pathological B cell activation. Without proper attenuation, B cells can become hyper-responsive, leading to autoantibody production and autoimmune pathology. Conversely, loss of negative regulators can contribute to B cell lymphomagenesis, as seen in Burkitt lymphoma where deregulated BCR signaling supports survival and proliferation. Moreover, the signaling threshold set by negative regulators influences B cell selection and chemotaxis, processes critical for proper immune responses. Thus, GO:0050859 represents a nexus of molecular mechanisms with broad implications for immunology, hematology, and oncology.
• Prevents autoimmunity by dampening self-reactive B cell activation.
• Controls B cell selection thresholds and anergy induction.
• Limits B cell chemotaxis and migration to inflammatory sites.
• Suppresses lymphomagenesis by restraining oncogenic BCR signaling.
• Modulates therapeutic responses to glucocorticoids in aggressive lymphomas.
• Influences primary atopic disorders and immune dysregulation.
• Provides targets for immunomodulatory drugs (e.g., BTK inhibitors, PI3K inhibitors).
• Regulates cytoskeletal dynamics required for B cell activation.
• Sets signaling strength of the AKT pathway to determine negative selection.
• Offers biomarkers for B cell-related diseases and treatment stratification.
What Happens During negative regulation of B cell receptor signaling pathway?
Initiation of BCR signaling and early negative feedback
In simple terms: When a B cell encounters an antigen, its receptor sends an activating signal, but the cell quickly applies brakes to prevent overreaction.
Antigen-induced cross-linking of the BCR triggers phosphorylation of immunoreceptor tyrosine-based activation motifs (ITAMs) by SRC-family kinases, leading to recruitment of SYK and activation of downstream pathways. Early negative feedback is mediated by inhibitory receptors such as FcγRIIB, which recruit SHIP1 to hydrolyze PIP3 and dampen PI3K signaling. This rapid attenuation is crucial for setting the threshold of B cell activation.
Phosphatase-mediated attenuation
In simple terms: Enzymes called phosphatases remove phosphate groups from signaling proteins, effectively turning off the signal.
SHIP1, SHP1, and PTEN are key phosphatases that negatively regulate BCR signaling. SHIP1 dephosphorylates PIP3 to PIP2, reducing AKT activation. SHP1 dephosphorylates SYK and other tyrosine kinases, while PTEN opposes PI3K activity. Loss of these phosphatases leads to hyperactive BCR signaling and autoimmunity in mouse models.
Ubiquitination and degradation of signaling components
In simple terms: Tagging signaling proteins with ubiquitin marks them for destruction, which shuts down the signal.
E3 ubiquitin ligases such as CBL, CBLB, and ITCH target activated BCR signaling molecules for ubiquitination and degradation. CBL ubiquitinates SYK and other kinases, promoting their proteasomal degradation. This mechanism provides a sustained negative feedback loop that prevents prolonged signaling.
Cytoskeletal regulation and signal termination
In simple terms: The cell's internal skeleton helps organize and then dismantle signaling complexes at the membrane.
Non-muscle myosin II is essential for the negative regulation of BCR signaling and B cell activation. It mediates the contraction of actin networks that disperse signaling microclusters, thereby terminating BCR signaling. Disruption of non-muscle myosin II leads to sustained BCR signaling and enhanced B cell activation.
Transcriptional and signaling threshold control
In simple terms: Certain transcription factors and signaling molecules set how sensitive a B cell is to activation, influencing whether it survives or is eliminated.
Ikaros regulates the signaling strength of the AKT pathway to set the threshold for negative B cell selection. p66Shc negatively regulates chemokine receptor signaling and B cell chemotaxis, thereby modulating B cell migration and positioning. These regulators integrate BCR signals with survival and migratory decisions.
Key Genes Involved in GO:0050859 negative regulation of B cell receptor signaling pathway
The following genes and proteins are central to the negative regulation of B cell receptor signaling pathway (GO:0050859), as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SHIP1 (INPP5D) | Hydrolyzes PIP3 to PIP2, dampening PI3K/AKT signaling | Autoimmunity, B cell anergy, lymphoma |
| SHP1 (PTPN6) | Dephosphorylates SYK and other kinases | B cell tolerance, immunodeficiency |
| PTEN | Lipid phosphatase opposing PI3K | Autoimmunity, lymphoma, B cell selection |
| CBL | E3 ubiquitin ligase targeting SYK for degradation | Negative feedback, B cell activation |
| CBLB | E3 ubiquitin ligase regulating BCR signaling | Autoimmunity, B cell tolerance |
| ITCH | E3 ubiquitin ligase modulating BCR signaling | Immune regulation, anergy |
| FcγRIIB (FCGR2B) | Inhibitory receptor recruiting SHIP1 | Autoimmunity, B cell inhibition |
| p66Shc (SHC1) | Negative regulator of chemokine receptor signaling and chemotaxis | B cell migration, inflammation |
| Ikaros (IKZF1) | Transcription factor setting AKT signaling threshold | B cell selection, leukemia |
| Non-muscle myosin II (MYH9/MYH10) | Cytoskeletal motor terminating BCR signaling | B cell activation, immune synapse |
| CD22 (SIGLEC2) | Inhibitory co-receptor recruiting SHP1 | B cell tolerance, autoimmunity |
| CD72 | Inhibitory receptor modulating BCR signaling | B cell development, autoimmunity |
| PIR-B (LILRB3) | Inhibitory receptor recruiting SHP1 | B cell inhibition, tolerance |
| SHP2 (PTPN11) | Tyrosine phosphatase with context-dependent roles | B cell signaling, immunodeficiency |
| DOK1 | Adaptor protein recruiting inhibitory molecules | B cell signaling attenuation |
| DOK3 | Adaptor protein negatively regulating BCR signaling | B cell activation, tolerance |
| GAB1 | Scaffold protein modulating PI3K signaling | B cell signaling, lymphoma |
| BANK1 | Scaffold protein regulating BCR signaling | Autoimmunity, B cell activation |
How Is negative regulation of B cell receptor signaling pathway Regulated?
The negative regulation of BCR signaling is itself subject to regulation by various mechanisms. Glucocorticoids can modulate BCR signaling components, contributing to their therapeutic efficacy in aggressive lymphomas. The proteasome-guided haem signalling axis has been implicated in T cell exhaustion, suggesting broader metabolic control of immune signaling. Additionally, the signaling threshold set by Ikaros is regulated by AKT pathway activity, which in turn is influenced by upstream phosphatases and kinases. These layers of regulation ensure that BCR signaling is appropriately tuned to environmental cues.
negative regulation of B cell receptor signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SHIP1 (INPP5D) | Autoimmunity, lymphoma | Knockout mouse, CRISPR KO in B cell lines |
| PTEN | Burkitt lymphoma, autoimmunity | Conditional knockout, point mutation |
| FCGR2B | Systemic lupus erythematosus | Knock-in of risk variants |
| PTPN6 (SHP1) | Immunodeficiency, autoimmunity | CRISPR KO, overexpression |
| IKZF1 (Ikaros) | B cell acute lymphoblastic leukemia | Point mutation, knockout |
Burkitt lymphoma
Burkitt lymphoma is characterized by deregulated BCR signaling, often due to mutations in genes such as MYC and components of the BCR pathway. Negative regulators like SHIP1 and PTEN are frequently inactivated, leading to constitutive PI3K/AKT signaling that supports tumor survival. Targeting these pathways is a therapeutic strategy.
Primary atopic disorders
Primary atopic disorders can result from mutations in genes that regulate BCR signaling, leading to immune dysregulation and allergic inflammation. Rapid genomic sequencing has identified variants in negative regulators such as PTPN6 and INPP5D in patients with severe atopy.
Autoimmune diseases
Defects in negative regulation of BCR signaling contribute to autoimmunity. For example, polymorphisms in FCGR2B and PTPN22 are associated with systemic lupus erythematosus and other autoimmune conditions. Mouse models with deletions in SHIP1 or SHP1 develop autoimmune phenotypes.
B cell immunodeficiencies
Conversely, excessive negative regulation can lead to immunodeficiency. Mutations in genes such as PTPN11 (SHP2) can impair B cell activation and antibody responses. Understanding the balance is crucial for diagnosing and treating these disorders.
From negative regulation of B cell receptor signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate BCR signaling? | CRISPR knockout in B cell lines (e.g., Ramos, DT40) |
| Does a specific point mutation in gene X alter its inhibitory function? | Point-mutation knock-in via CRISPR |
| Does overexpression of gene X suppress BCR signaling? | Overexpression cell model |
| Where does gene X localize during BCR activation? | Tagged knock-in (e.g., GFP) and imaging |
| Does gene X regulate B cell activation in vivo? | Conditional knockout mouse |
| Can gene X be targeted therapeutically? | CRISPR library screening for modifiers of BCR signaling |
How to Study the negative regulation of B cell receptor signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Phospho-proteomics | Global tyrosine phosphorylation changes | Identify signaling nodes after BCR activation |
| CRISPR knockout screening | Gene essentiality or modifier status | Discover negative regulators of BCR signaling |
| TIRF microscopy | Microcluster dynamics at the plasma membrane | Visualize signal termination |
| Calcium flux assay | Intracellular calcium mobilization | Measure B cell activation strength |
| Flow cytometry | Surface marker expression and proliferation | Assess B cell activation and differentiation |
| Immunoblotting | Protein phosphorylation and degradation | Validate specific signaling events |
| RNA-seq | Transcriptional changes | Identify gene expression programs downstream of BCR |
| Proximity ligation assay | Protein-protein interactions | Detect recruitment of inhibitory complexes |
Phospho-proteomics
Phospho-proteomics allows global profiling of tyrosine phosphorylation events following BCR cross-linking, revealing changes in signaling cascades upon modulation of negative regulators. This method can identify novel substrates of phosphatases and kinases.
CRISPR screening
Genome-wide CRISPR knockout or activation screens can identify genes that negatively regulate BCR signaling. For example, a screen for modifiers of BCR-induced calcium flux can uncover novel inhibitory pathways.
Imaging and live-cell microscopy
Total internal reflection fluorescence (TIRF) microscopy and live-cell imaging visualize the assembly and disassembly of BCR microclusters, providing spatial and temporal insights into negative regulation.
Functional assays
B cell activation assays measuring calcium mobilization, proliferation, and antibody secretion are used to assess the impact of negative regulators. These assays are often combined with genetic perturbations.
How CRISPR Can Be Used to Study GO:0050859 negative regulation of B cell receptor signaling pathway
Knockout
CRISPR knockout of candidate negative regulators (e.g., SHIP1, PTEN) in B cell lines or primary B cells can reveal their role in dampening BCR signaling. Loss of function typically leads to enhanced calcium flux, ERK phosphorylation, and proliferation.
Point Mutation
Point mutations in catalytic domains or interaction motifs of negative regulators can dissect their mechanism. For example, a phosphatase-dead mutant of SHIP1 can be knocked in to test whether catalytic activity is required for BCR suppression.
Knock-in
Knock-in of tagged versions (e.g., GFP, HA) of negative regulators allows visualization and immunoprecipitation. This approach helps track localization and complex formation during BCR activation.
Overexpression
Overexpression of negative regulators can suppress BCR signaling and B cell activation. This is useful for gain-of-function studies and for testing therapeutic potential of enhancing inhibitory pathways.
How EDITGENE Supports negative regulation of B cell receptor signaling pathway Research
Researchers studying negative regulation of B cell receptor signaling pathway-related genes often need to determine whether a candidate gene is causally involved in dampening BCR signaling, and to dissect the precise molecular mechanism. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of B cell receptor signaling pathway research.
Frequently Asked Questions About negative regulation of B cell receptor signaling pathway
What is GO:0050859?
GO:0050859 is the Gene Ontology term for negative regulation of B cell receptor signaling pathway, defined as any process that stops, prevents, or reduces the frequency, rate or extent of signaling pathways initiated by cross-linking of an antigen receptor on a B cell.
What genes are involved in negative regulation of B cell receptor signaling pathway?
Key genes include SHIP1 (INPP5D), SHP1 (PTPN6), PTEN, CBL, CBLB, ITCH, FCGR2B, p66Shc (SHC1), Ikaros (IKZF1), and non-muscle myosin II (MYH9/MYH10).
Why is negative regulation of BCR signaling important?
It prevents autoimmunity, limits lymphomagenesis, and sets thresholds for B cell selection and activation.
What diseases are linked to defects in BCR signaling inhibition?
Burkitt lymphoma, primary atopic disorders, autoimmune diseases like lupus, and B cell immunodeficiencies.
How can I study negative regulation of BCR signaling?
Use CRISPR knockout, point mutation, knock-in, overexpression models combined with phospho-proteomics, imaging, and functional assays.
What is the role of phosphatases in BCR signaling?
Phosphatases such as SHIP1, SHP1, and PTEN remove phosphate groups from signaling lipids and proteins, thereby attenuating BCR signaling.
How does non-muscle myosin II regulate BCR signaling?
Non-muscle myosin II mediates contraction of actin networks that disperse signaling microclusters, terminating BCR signaling.
What is the role of Ikaros in B cell selection?
Ikaros regulates the signaling strength of the AKT pathway to set the threshold for negative B cell selection.
Can CRISPR screens identify new negative regulators of BCR signaling?
Yes, genome-wide CRISPR screens can uncover novel genes that modulate BCR signaling when knocked out or overexpressed.
What experimental models are available for studying GO:0050859?
Knockout, point mutation, knock-in, and overexpression cell models, as well as CRISPR library screening and bioinformatics services from EDITGENE.
Conclusion
GO:0050859, negative regulation of B cell receptor signaling pathway, encompasses a sophisticated network of phosphatases, ubiquitin ligases, adaptor proteins, and cytoskeletal regulators that together ensure appropriate B cell responses. Dysregulation of these mechanisms underlies a spectrum of human diseases, from autoimmunity to B cell malignancies. Continued research using advanced CRISPR models and multi-omics approaches will further illuminate these pathways and identify new therapeutic targets. EDITGENE stands ready to support these efforts with tailored gene editing and screening services.
References
- 1. Tanaka S et al.. 2020. B Cell Receptor Signaling.. Adv Exp Med Biol 1254:23-36 PMID: 32323266
- 2. Choi J et al.. 2024. Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas.. Cancer Cell 42(5):833-849.e12 PMID: 38701792
- 3. Niehues T et al.. 2024. Rapid identification of primary atopic disorders (PAD) by a clinical landmark-guided, upfront use of genomic sequencing.. Allergol Select 8:304-323 PMID: 39381601
- 4. Schmitz R et al.. 2012. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.. Nature 490(7418):116-20 PMID: 22885699
- 5. Xu Y et al.. 2026. Proteasome-guided haem signalling axis contributes to T cell exhaustion.. Nature 653(8114):548-557 PMID: 41851457
- 6. Patrussi L et al.. 2014. Negative regulation of chemokine receptor signaling and B-cell chemotaxis by p66Shc.. Cell Death Dis 5(2):e1068 PMID: 24556683
- 7. Ehm PAH et al.. 2024. Ikaros sets the threshold for negative B-cell selection by regulation of the signaling strength of the AKT pathway.. Cell Commun Signal 22(1):360 PMID: 38992657
- 8. Seeley-Fallen MK et al.. 2022. Non-Muscle Myosin II Is Essential for the Negative Regulation of B-Cell Receptor Signaling and B-Cell Activation.. Front Immunol 13:842605 PMID: 35493485
